Xiong Xi, Cui Yun, Wang Chunxia, Zhou Yiping, Ma Xiaoxuan, Li Pin, Zhang Yucai
Department of Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
Laboratory of Critical Care Translational Medicine, Institute of Pediatric Infection, Immunity, and Critical Care Medicine, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200062, China.
BMC Pulm Med. 2025 Mar 26;25(1):136. doi: 10.1186/s12890-025-03598-w.
The number of malignancy patients with respiratory failure is rising in pediatric intensive care units (PICU). Our study aims to compare the clinical characteristics and prognostic risk factors of acute respiratory distress syndrome (ARDS) with or without malignancies.
This retrospective study reviewed medical records of 188 ARDS patients admitted to the PICU between January 2018 and December 2022, including 60 with malignancies and 128 without. Clinical data were collected within 48 h post-ARDS diagnosis. Multivariate logistic regression analysis and receiver operating characteristic curve (ROC) analysis were used to investigate the risk factors for PICU mortality in the malignancy and non-malignancy groups.
Compared with pediatric patients without malignancy, the ARDS patients with malignancy presented higher mortality (55.0% vs. 31.3%, P = 0.002), a higher incidence of community-acquired fungal infection (36.1% vs. 6.3%, P < 0.001) and multidrug resistance (MDR) bacteria (65.4% vs. 30.5%, P = 0.003). There were substantial differences in levels of lactate [1.5 (0.8-3.7) vs. 1.0 (0.7-2.0) mmol/L, P = 0.008], C-reactive protein (CRP) [150.0 (83.0-168.0) vs. 31.0 (10.0-108.0) mg/L, P = 0.02], procalcitonin (PCT) [10.4 (2.0-27.5) vs. 1.2 (0.3-6.2) mg/L, P < 0.001], counts of platelet [17.0 (8.0-73.0) vs. 232.0 (152.0-330.0) × 10/µL, P < 0.001], the distribution of CD8 + T [36.9 (26.0-53.6) vs. 21.9 (17.3-29.1) %, P < 0.001], CD19 + T cells [9.9 (0.9-30.2) vs. 33.6 (22-46.6) %, P < 0.001], and higher peak vasoactive-inotropic score (VIS) in ARDS with malignancy [73.0 (20-208) vs. 15.0 (5.0-82.0), P < 0.01]. In multivariable analysis, only VIS independently predicted mortality in ARDS patients with malignancy (OR, 1.011; 95% confidence interval [CI]: 1.003-1.018; P = 0.005). Neither pSOFA scores (OR, 1.249, 95% CI: 0.958-1.628, P = 0.101) nor lactate levels (OR, 1.192, 95% CI: 0.928-1.531, P = 0.170) showed significant associations.
ARDS patients with malignancies exhibited poorer outcomes. VIS is only an independent predictor of mortality in pediatric ARDS patients with malignancies.
儿科重症监护病房(PICU)中合并呼吸衰竭的恶性肿瘤患者数量正在增加。我们的研究旨在比较合并或不合并恶性肿瘤的急性呼吸窘迫综合征(ARDS)的临床特征和预后危险因素。
这项回顾性研究回顾了2018年1月至2022年12月期间入住PICU的188例ARDS患者的病历,其中60例合并恶性肿瘤,128例未合并。在ARDS诊断后48小时内收集临床数据。采用多因素逻辑回归分析和受试者工作特征曲线(ROC)分析,研究恶性肿瘤组和非恶性肿瘤组PICU死亡率的危险因素。
与无恶性肿瘤的儿科患者相比,合并恶性肿瘤的ARDS患者死亡率更高(55.0%对31.3%,P = 0.002),社区获得性真菌感染发生率更高(36.1%对6.3%,P < 0.001),多重耐药(MDR)菌感染发生率更高(65.4%对30.5%,P = 0.003)。乳酸水平[1.5(0.8 - 3.7)对1.0(0.7 - 2.0)mmol/L,P = 0.008]、C反应蛋白(CRP)[150.0(83.0 - 168.0)对31.0(10.0 - 108.0)mg/L,P = 0.02]、降钙素原(PCT)[10.4(2.0 - 27.5)对1.2(0.3 - 6.2)mg/L,P < 0.001]、血小板计数[17.0(8.0 - 73.0)对232.0(152.0 - 330.0)×10⁹/µL,P < 0.001]、CD8⁺T细胞分布[36.9(26.0 -